|
Title
|
Published
|
Price
|
|
Mobile gaming 2007-2012: Will Sony Ericsson's PSP Variant be a Catalyst for the Market?
By: Visiongain
The brand new mobile gaming report from visiongain says that mobile gaming showing signs of slowdown due to rising costs.
Since 2003, much anticipation has surrounded the nascent mobile gaming business, a new area
|
more...
|
10/3/2007
|
$2,210.00
|
|
The World Diabetes Market, 2006-2025
By: Visiongain
Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and
|
more...
|
10/3/2007
|
$2,210.00
|
|
The World Hypertension Market 2007-2023
By: Visiongain
The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or
|
more...
|
9/17/2007
|
$2,210.00
|
|
Service Delivery Platforms & Service Orientated Architecture Report 2007-2012
By: Visiongain
Service Delivery Platforms (SDPs) generally simplify architectures, eliminate the need for costly and inflexible vertical structures and also significantly reduce the need for specialized skills in the service development field. Through the use of SDPs
|
more...
|
9/17/2007
|
$2,210.00
|
|
Mobile Security & Anti-virus Report
By: Visiongain
Malware is targeting mobile phones and networks. So far it hasn't been as infectious as its PC counterparts, but visiongain believes it is only a matter of time before a large scale case makes network
|
more...
|
8/15/2007
|
$2,210.00
|
|
Ultra Low Cost Handsets 2007-2012: Market Analysis and Forecasts of 2G & 3G Communications in Developing Markets
By: Visiongain
Ultra Low Cost Handsets (ULCH) are critical for subscriber growth in emerging markets and for the growth of 3G services in both emerging and saturated markets. Since 2005, the ULCH strategy for emerging markets has
|
more...
|
8/10/2007
|
$2,210.00
|
|
Multiple Sclerosis Market Analysis & Forecasts Report 2007-2022
By: Visiongain
The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate
|
more...
|
8/2/2007
|
$2,210.00
|
|
Qualcomm : Insight & Market Analysis 2007- 2012
By: Visiongain
The year 2007 has so far proven difficult for US technology giant, Qualcomm, having spawned consecutive setbacks in its IPR battles with chipmaker Broadcom and mobile phone manufacturer Nokia. However, focusing purely on such divisive
|
more...
|
8/1/2007
|
$2,210.00
|
|
M-Payments 2007-2012: Commerce and banking in the mobile world
By: Visiongain
Mobile payments are set to make a significant impact on the world of banking and commerce within the next five years. Handsets can now be used to buy online, via ‘swipe’ points in retail outlets,
|
more...
|
7/27/2007
|
$2,210.00
|
|
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge of Turning Technology into Therapy
By: Visiongain
Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large
|
more...
|
7/23/2007
|
$2,210.00
|
|
Vodafone Insight 2007 - Acquisition, Management Change & Caution
By: Visiongain
LATEST BREAKING NEWS - Vodafone deny plans to buy Verizon.
Brand new report examines Vodafone's strategy and examine, country by country the company's footprint. How does this company affect you?
Vodafone
|
more...
|
7/19/2007
|
$2,210.00
|
|
Anti-Obesity Treatments 2007-2012 - A blockbuster target market
By: Visiongain
“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”. For pharmaceutical companies looking to target growing successful markets,
|
more...
|
7/13/2007
|
$2,210.00
|
|
Location Based Advertising 2007-2012: maximising the revenue potential of location discovery
By: Visiongain
Location Based Advertising 2007-2012: maximising the revenue potential of location discovery
Location Based Advertising is already here and starting to happen. The ability to target consumers based on their locale will
|
more...
|
7/6/2007
|
$2,210.00
|
|
Global Smoking Cessation Market Analysis & Forecasts - Preparing for the First Blockbuster
By: Visiongain
Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking
|
more...
|
7/4/2007
|
$2,210.00
|
|
Lou Gehrig Disease Report - Is there a link between Lipitor and ALS?
By: Visiongain
Lou Gehrig Disease Report - Is there a link between Lipitor and ALS?
Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease in the US, Maladie de Charcot in France and Motor Neuron
|
more...
|
7/1/2007
|
$2,210.00
|
|
TD-SCDMA and the Chinese 4G Trials, Vendors and Handset Manufacturers
By: Visiongain
Chinese technology vendors have been struggling with high patent fees as they loose at least 5% of their sales income to royalty costs if they adopt WCDMA or CDMA 2000 technology in their equipment. The
|
more...
|
6/29/2007
|
$2,210.00
|
|
Parallel Trade - US Lawmakers Allow Imported Prescriptions Drugs
By: Visiongain
"Parallel Trade acts as an important driving force for market integration where there are important differences in price between member states"
- European Commission Communication on the single market in pharmaceuticals
Parallel trade
|
more...
|
6/21/2007
|
$2,210.00
|
|
DVB-H Mobile TV Services - Demand, Handsets, Analysis & Forecasts to 2012
By: Visiongain
Mobile TV will be successful. DVB-H is the one technology that has gained headway in Europe and the US, but various alternatives remain. Questions still remain about demand, cost-effectiveness, user's willingness to pay and handset
|
more...
|
6/19/2007
|
$2,210.00
|
|
Rimonabant: The First of the Cannabinoid Blockbusters
By: Visiongain
Marinol®, Cesamet®, Sativex ® and Rimonabant are all commercially-marketed cannabinoids. They treat a variety of conditions from weight-loss to pain relief. The introduction of cannabinoids into the pharmaceutical marketplace has begun, and attitudes to the
|
more...
|
6/15/2007
|
$2,210.00
|
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
By: Visiongain
With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries.
But Alzheimer's isn't the only neurodegenerative disease and
|
more...
|
6/15/2007
|
$2,210.00
|
|
Microsoft in Mobile (TM): Market analysis and forecasts 2007-2012
By: Visiongain
Microsoft(TM) has been one of the companies driving the digital age, making the internet and digital entertainment accessible to the masses and improving enterprise productivity. Having expanded its business operations into the mobile telecoms industry,
|
more...
|
5/30/2007
|
$2,210.00
|
|
Gastrointestinal Disorders Market Intelligence to 2012
By: Visiongain
Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will
|
more...
|
5/25/2007
|
$2,210.00
|
|
Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012
By: Visiongain
Teva has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global
|
more...
|
5/17/2007
|
$2,210.00
|
|
Global Ophthalmic Market Analysis & Forecasts to 2012
By: Visiongain
Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012.
|
more...
|
4/30/2007
|
$2,210.00
|
|
Mobile Music Stores 2007-2012: Will A Mobile-focussed Solution Hold More Potential Than Microsoft, Nokia Or Even Apple'S Itunes' Ambitions In Ota Downloads?
By: Visiongain
Mobile music downloading is on the increase. The market for full-track music
downloads to mobile devices approximately doubled in 2006. Will this
adoption rate continue? How can your company benefit from being involved in
this
|
more...
|
4/17/2007
|
$2,210.00
|
|
Title
|
Published
|
Price
|
(0 items)
